B. Riley’s Top Biotech Picks Ahead of 3Q26 Earnings Season
B. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
How this was made
The 30-second read
Why it matters
The recommendations could drive short‑term price moves in the highlighted stocks as investors adjust positions before earnings.
Market read
The article offers actionable buy ratings for six biotech companies, potentially influencing trading activity in the sector.
What to watch
Potential impact of higher interest rates on biotech financing costs.
Background
Analyst B. Riley provides a list of top biotech picks with ratings and price targets ahead of the upcoming earnings season.
Ticker impact
Analyst rates Axsome Therapeutics Buy with $300 target and cites Q3 revenue guidance.
price may rise toward target if Q3 results align with forecasts.
Buy rating and price target provide a clear actionable view.
Analyst rates Cytokinetics Buy with $146 target, highlighting Q3 wholesale volume growth.
stock may rally on strong volume data.
Volume data and target suggest near‑term upside.
Analyst rates Eton Pharmaceuticals Buy with $70 target, noting margin expansion and revenue guidance.
price could climb if guidance holds.
Guidance above consensus signals positive catalyst.
Analyst rates Harrow Buy with $60 target, providing Q3 and Q4 revenue estimates.
stock may appreciate toward target.
Targeted revenue figures give a clear valuation basis.
Analyst rates TG Therapeutics Buy with $86 target, citing upcoming Phase 3 data and Briumvi run‑rate.
stock may rise ahead of trial readout.
Phase 3 expectations create near‑term catalyst.
Analyst rates Zymeworks Buy with $44 target, referencing Jazz partnership launch data.
price could move toward target on launch progress.
Partnership revenue adds growth potential.
Market effects
Biotech sector may see broader buying interest as analyst upgrades multiple names.
U.S. small‑cap biotech stocks could benefit.
Limited to investors focused on U.S. biotech equities.
Counterpoint
Some investors may view the upgrades as overly optimistic given macro‑driven drawdown risk.
Key entities
- Research FirmB. Riley
Provides analyst ratings and price targets for biotech stocks.
